References
- de Vries ME, Boddé HE, Verhoef JC, Junginger HE. Developments in buccal drug delivery. Crit Rev Ther Drug Carrier Syst 1991;8:271–303
- Campisi G, Paderni C, Saccone, R, et al. Human buccal mucosa as an innovative site of drug delivery. Curr Pharm Des 2010;16:641–652
- Hoogstraate A, Senel J, Cullander S, et al. Effects of bile salts on transport rates and routes of FITC-labelled compounds across porcine buccal epithelium in vitro. J Control Release 1996;40:211–221
- Senel S, Capan Y, Sargon MF, et al. Enhancement of transbuccal permeation of morphine sulfate by sodium glycodeoxycholate in vitro. J Control Release 1997;45:153–162
- Figueiras A, Hombach J, Veiga F, Bernkop-Schnürch A. In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm 2009;71:339–345
- Ayensu I, Mitchell JC, Boateng JS. Development and physico-mechanical characterisation of lyophilised chitosan wafers as potential protein drug delivery systems via the buccal mucosa. Colloids Surf B Biointerfaces 2012;91:258–265
- Sandri G, Rossi S, Bonferoni MC, et al. Buccal penetration enhancement properties of N-trimethyl chitosan: influence of quaternization degree on absorption of a high molecular weight molecule. Int J Pharm 2005;297:146–155
- Langoth N, Kahlbacher H, Schöffmann G, et al. Thiolated chitosans: design and in vivo evaluation of a mucoadhesive buccal peptide drug delivery system. Pharm Res 2006;23:573–579
- Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49:S58–S62
- Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000;60:115–137
- Contin M, Martinelli P. Pharmacokinetics of levodopa. J Neurol 2010;257:S253–S261
- Ahlskog JE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson’s disease. Physiol Behav 2011;104:168–172
- Lesch CA, Squier CA, Cruchley A, et al. The permeability of human oral mucosa and skin to water. J Dent Res 1989;68:1345–1349
- Diaz Del Consuelo I, Pizzolato G, Falson F, et al. Evaluation of pig esophageal mucosa as a permeability barrier model for buccal tissue. J Pharm Sci 2005;94:2777–2788
- Sieval A, Thanou BM, Kotzé AF, et al. Preparation and NMR characterization of highly substituted N-trimethyl chitosan chloride. Carbohydr Polym 1998;36:157–165
- Hamman JH, Kotzé AF. Effect of the type of base and number of reaction steps on the degree of quaternization and molecular weight of N-trimethyl chitosan chloride. Drug Dev Ind Pharm 2001;27:373–380
- Irie T, Wakamatsu K, Arima H, et al.. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int J Pharm 1992;84:129–139
- Masson M, Loftsson T, Másson G, Stefánsson E. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing. J Control Release 1999;59:107–118
- Schwarz J, Pagitsch C, Valenta EC. Comparison of ATR-FTIR spectra of porcine vaginal and buccal mucosa with ear skin and penetration analysis of drug and vehicle components into pig ear. Eur J Pharm Sci 2013;50:595–600
- McCormack B, Gregoriadis G. Comparative studies of the fate of free and liposome-entrapped hydroxypropyl-beta-cyclodextrin/drug complexes after intravenous injection into rats: implications in drug delivery. Biochim Biophys Acta 1996;1291:237–244
- Khan S, Boateng JS, Mitchell J, Trivedi V. Formulation, characterisation and stabilisation of buccal films for paediatric drug delivery of omeprazole. AAPS PharmSciTech 2015;16:800–810
- Boateng JS, Mitchell JC, Pawar H, Ayensu I. Functional characterisation and permeation studies of lyophilised thiolated chitosan xerogels for buccal delivery of insulin. Protein Pept Lett 2014;21:1163–1175
- Moscicka-Studzinska A, Kijeńska E, Ciach T. Electroosmotic flow as a result of buccal iontophoresis-buccal mucosa properties. Eur J Pharm Biopharm 2009;72:595–599